2024 Impact Report
Ushering In a New Era of Progress
Cure JM is proud to have invested $27 million in research for better juvenile myositis treatments, care, and support.
Our network of researchers spans the globe, and we are proud to have:
- Reduced diagnosis time by 75%, from 12 months to 3 months
- Improved care and outcomes through our Clinical Care Network and clinician education programs
- Invested in research and partnerships to advance new treatments, like deucravacitinib, CAR-T, and others
- Supported families navigating juvenile myositis with the essential resources, guidance, and tools they need
Together, we are entering a new era of progress in the fight against juvenile myositis. Your continued support is transforming lives and bringing hope to children and families.